Using epidemiology and archaeology to unearth new drug targets for rheumatoid arthritis therapy.
Epidemiological and archaeological evidence suggests that RA could be a consequence of enhanced immunity to Mycobacterium tuberculosis, and that by understanding this connection, new RA drug targets may be uncovered.
Mobley
James L
JL
Department of Inflammation Pharmacology, Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105, USA. james.mobley@pfizer.com
D018501:Antirheumatic Agents; D001106:Archaeology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D006801:Humans; D007113:Immunity, Innate / Q000235:genetics*; D014376:Tuberculosis / Q000235:genetics* / Q000276:immunology
D018501:Antirheumatic Agents